Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more
Insight Molecular Diagnostics Inc. (IMDX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.490x
Based on the latest financial reports, Insight Molecular Diagnostics Inc. (IMDX) has a cash flow conversion efficiency ratio of 0.490x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.50 Million) by net assets ($-9.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Insight Molecular Diagnostics Inc. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Insight Molecular Diagnostics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Insight Molecular Diagnostics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Insight Molecular Diagnostics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Urban View Development Spain SOCIMI S.A.
MC:YUVS
|
N/A |
|
Poh Kong Holdings Bhd
KLSE:5080
|
0.026x |
|
AIFORIA TECHNOLOGIES OYJ
F:L6J
|
N/A |
|
GUNOSY INC.
F:6GU
|
N/A |
|
Mnc Kapital Indonesia Tbk
JK:BCAP
|
0.136x |
|
e-LITECOM CO. Ltd
KQ:041520
|
-0.006x |
|
Birchtech Corp.
OTCQB:BCHT
|
-0.281x |
|
MS Industrie AG
F:MSAG
|
0.082x |
Annual Cash Flow Conversion Efficiency for Insight Molecular Diagnostics Inc. (2013–2024)
The table below shows the annual cash flow conversion efficiency of Insight Molecular Diagnostics Inc. from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.27 Million | $-20.71 Million | 1.688x | +248.08% |
| 2023-12-31 | $20.47 Million | $-23.32 Million | -1.140x | +0.98% |
| 2022-12-31 | $39.59 Million | $-45.57 Million | -1.151x | -108.83% |
| 2021-12-31 | $65.22 Million | $-35.94 Million | -0.551x | +28.97% |
| 2020-12-31 | $33.48 Million | $-25.98 Million | -0.776x | -21.37% |
| 2019-12-31 | $30.84 Million | $-19.71 Million | -0.639x | +81.21% |
| 2018-12-31 | $3.42 Million | $-11.65 Million | -3.403x | -11.95% |
| 2017-12-31 | $4.40 Million | $-13.38 Million | -3.040x | -298.57% |
| 2016-12-31 | $9.86 Million | $-7.52 Million | -0.763x | -87.88% |
| 2015-12-31 | $10.42 Million | $-4.23 Million | -0.406x | -137.46% |
| 2014-12-31 | $-1.07 Million | $-1.16 Million | 1.084x | +651.82% |
| 2013-12-31 | $3.62 Million | $-710.00K | -0.196x | -- |